Alzheimer's disease is the most common cause of dementia, accounting for 60-80% of all cases in the United States.
1 It is clinically diagnosed based on the presence of cognitive impairment that severely interferes with the activities of daily living. A pathological diagnosis is only possible after verification of the presence of amyloid β plaques in brain tissue. Misdiagnosis may lead to unnecessary treatment, worsening outcomes, and inefficient or inappropriate use of healthcare resources.
In April 2012 florbetapir 18 F, marketed as Amyvid by Eli Lilly, became the first radioactive diagnostic agent to be approved by the Food and Drug Administration for positron emission tomography (PET) of the brain to evaluate amyloid β neuritic plaque density. Subsequently two similar PET agents, flutemetamol 18 F (Vizamyl, GE Healthcare) and florbetaben 18 F (Neuraceq, Piramel Imaging) were approved. The European Medicines Agency has also granted marketing authorization to all three agents. Although they are considered to be both drugs and diagnostics, their use is for diagnostic purposes only.
All three agents can rule out Alzheimer's disease but cannot provide a positive diagnosis. The FDA and European Medicines Agency labels for florbetapir include two important caveats-that a positive scan does not definitively establish a diagnosis of Alzheimer's disease and that the safety and effectiveness of florbetapir have not been established for predicting the onset of dementia. 2 Florbetapir scans cost approximately $3000 (£1890; €2640) for those who don't have insurance to cover the cost. Medicare coverage is statutorily limited to items and services that are considered "reasonable and necessary" for the diagnosis or treatment of an illness or injury. 3 Diagnostics are covered under the same component of Medicare (Part B) as physician administered drugs.
FDA approval is a necessary but insufficient condition for diagnostic coverage by Medicare. Manufacturers must also demonstrate the clinical utility of a diagnostic by linking the test's use to improved health outcomes compared with a standard diagnostic work-up. Conversely, FDA approval is both necessary and sufficient for physician administered drugs, with the notable exception of off-label uses that are cited in officially sanctioned medical compendiums.
The US Centers for Medicare and Medicaid Services routinely covers all FDA approved uses for physician administered drugs, but only 75% of FDA approved diagnostics. Here we discuss how the decision on florbetapir was made and argue for consistent coverage criteria.
Medicare decision on florbetapir
After a lengthy evaluation of florbetapir's effects on health outcomes, the US Centers for Medicare and Medicaid Services decided in September 2013 to restrict coverage of florbetapir to Medicare beneficiaries who can pay for it out of pocket or are enrolled in clinical trials designed to demonstrate the test's clinical utility.
The decision not to routinely cover florbetapir was due to "insufficient evidence" to conclude that its use is reasonable and necessary. 4 A Medicare committee sought an expert panel's input on whether the evidence showed improved health outcomes for those who underwent PET amyloid β imaging with florbetapir compared with a standard diagnostic work-up without imaging, based on an assessment of cognitive and behavioral symptoms. 4 The panel voted using a 1-5 confidence scale, where 1 represents low or no confidence and 5 represents high confidence. The main question was, "How confident are you that there is adequate evidence to determine whether PET amyloid β imaging with florbetapir would change health outcomes (improve, be equal, worsen) in patients who display The completed program resulted in non-coverage for fluorodeoxyglucose PET scans for adenocarcinoma of the prostate, as well as coverage restrictions for scans of cancers of the cervix, breast, and melanoma. 5 Non-coverage was due to lack of evidence demonstrating usefulness of imaging tests to inform treatment strategies.
The objective of the CED program for florbetapir is to answer two questions. Firstly, does the use of florbetapir help guide patient management by selecting patients on the basis of biological, clinical, and epidemiological factors, thereby leading to better health outcomes, measured in terms of improved quality of life and extended survival? And secondly, can its use for patient selection improve the chances of successfully developing a drug for Alzheimer's disease?
Making florbetapir part of a CED program, however, elicited a negative reaction from the Alzheimer's community and drew critical comments from Eli Lilly. Critics have said that florbetapir was "well studied enough" to be used in a larger array of clinical settings than a CED program offers. 6 7 Critics also focused on the added cost and complexity of conducting a specially designed post-marketing clinical trial, as well as patient access restrictions, which includes delays caused by implementing a CED program. Notably, for all six diagnostics approved by the FDA the period between marketing approval and the CED start date was at least one year. Further, only one has been completed. Reasons for not completing trials include insufficient funding and lack of adequate data collection systems. 8 It is also unclear to what extent the Centers for Medicare and Medicaid Services will reimburse ancillary costs, such as personnel and overheads, related to imaging under this program.
Inconsistent coverage criteria
The Centers for Medicare and Medicaid Services does not routinely cover about 25% of FDA approved diagnostics, whereas it covers all FDA approved uses of physician administered drugs. 9 Moreover, no labeled use of a physician administered drug has been part of a CED program. And, with the exception of sipuleucel-T, the Centers for Medicare and Medicaid Services has not compared any approved uses of physician administered drugs with the existing standard of care. 10 This is particularly difficult to understand given that the evidence at launch for many newly approved drugs shows marginal benefit relative to existing treatment options. 11 12 The inconsistency in evaluations of new technology could be explained by the often limited evidence base for diagnostics at launch, compared with drugs. 13 However, this does not explain the higher standard of evidence applied to diagnostics than drugs.
Conspicuously, in December 2013 the UK NHS decided to cover florbetapir without imposing conditions of reimbursement. The UK National Institute for Health and Care Excellence stated that the value of diagnostic tests is best understood in the context of their effect on the treatment pathway of Alzheimer's disease rather than their direct impact on health outcomes. 14 15 For florbetapir, this implies assessment of the test's ability to provide useful information to guide treatment strategies and drug development. Policy makers should assess the test's ability to rule out Alzheimer's disease, to stratify subpopulations of patients so that those entering clinical trials are appropriately selected, and to reduce unnecessary treatment and patient anxiety.
The UK decision to cover florbetapir, as well as the reasons given for assessing diagnostics differently from drugs, suggest that the Centers for Medicare and Medicaid Services may be asking the wrong question-that is, whether they directly affect health outcomes of patients with Alzheimer's disease. In the absence of more effective treatment options, asking narrowly whether florbetapir has a direct impact on health outcomes, as the CED program does, would almost invariably be answered negatively. In light of the virtually automatic coverage of physician administered drugs, the Centers for Medicare and Medicaid Services seems reluctant to ask whether they improve health outcomes compared with existing treatment options.
Equal levels of scrutiny
We think that consistency is needed, both in terms of level of scrutiny and selection for coverage with evidence development, for drugs and diagnostics alike. We are not saying that the same criteria should be used for drugs and diagnostics, as this may not be appropriate. Proof of clinical utility is an appropriate criterion for some diagnostics, whereas whether they have a positive impact on treatment pathways is more appropriate for others. For drugs, proof of clinical effectiveness relative to existing treatments is the appropriate criterion.
A prudent approach would be for the Centers for Medicare and Medicaid Services to provide all Medicare beneficiaries with access to florbetapir for at least one indication, without linking reimbursement to enrollment in a post-marketing clinical trial. Medicare could still collect post-approval evidence on florbetapir's benefits and risks in the form of observational data from medical claims datasets. Benefits would be measured in broader terms than clinical utility, namely impact on treatment pathways. The manufacturers of florbetapir or similar PET diagnostics would gather emerging information on the benefits and harms of using such diagnostics in a real world setting.
The Centers for Medicare and Medicaid Services' coverage criteria under the rubric "reasonable and necessary" have never been clearly defined or implemented consistently across medical technologies. 3 We maintain that the criteria should be consistent for drugs and diagnostics, both in terms of level of scrutiny and selection for coverage with evidence development.
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